close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Choose your License

loading animation for AJAX calls

Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

REPORT HIGHLIGHTS

  • The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
  • Progressive dementia treatments are expected to have a value of $7.3 billion in 2012 and nearly $11 billion in 2017, a CAGR of 8.4%.
  • Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%.

SUMMARY FIGURE
GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017
($ MILLIONS)
GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017
To Contact us, click here  help


Source: BCC Research

REPORT SCOPE

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders.  The key objective is to present a comprehensive analysis and the future direction of the market as it shapes drug and therapy development.

This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders.  Market gains, setbacks and needs are discussed in this report.  Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.

A detailed analysis of the structure of the syndromes of dementia and movement disorder industry has been conducted. Revenues are broken down by neurodegenerative disease and primary clinical/pathological feature.  Sales figures are estimated for the five-year period from 2012 through 2017.

Applications for syndromes of dementia and movement disorder treatments, or therapeutic technologies, are also discussed separately in the report, with an emphasis on small molecule and monoclonal antibodies technology.  The report also covers significant patents and their allotment in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders.  New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction.  Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market.  This study looks at most of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report.  This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewy body dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration, Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease.  Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets.  BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share.  Technological issues include the latest trends and developments.  The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources.  Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors’ technical experts.  Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study.  Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries.  Data were gathered from various industry sources.  BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts.  Exhaustive investigations of databases by key terminology were completed.  In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

The study has been carried out by a team of professionals in the biotechnology industry.  The project manager for this study is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience.  Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid.  Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy—An Enduring Market; Advanced Drug Delivery Systems—Technologies and Global Markets; Orthopedic Drugs, Implants and Devices—Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry—The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging—Global Markets; Chiral Technology—Global Markets; Autacoids and Related Drugs—Technologies and Global Markets; Contraceptives—Technologies and Global Markets; Liver Disease Treatments—The Global Market; Hormone Replacement Therapies and Other Hormone Therapies—Global Markets; Cardiovascular Medicine—Diagnostics, Drugs and Devices; and Cancer Therapies − Technologies and Global Markets.

The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master’s degree in biophysics.  She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.

BCC ONLINE SERVICES

Now you can locate the hard-to-find information you need on the Internet’s World Wide Web.  By directing your browser to BCC Research’s “home page,” you will be able to do the following:

  • Examine its complete catalog of technology market research reports, tables of content, and order directly from BCC Research.
  • Subscribe to any of its more than 20 monthly technology/marketing newsletters.
  • Read announcements of upcoming reports and newly launched newsletters.
  • Register for BCC’s well-known conferences.
  • Request additional information about any BCC product.
  • Take advantage of special offers.

To reach this important information resource, go to www.bccresearch.com

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

REPORT TOC

Pricing on the website is provided for single users and 2-5 users licenses only. Please contact us at (+1)781-489-7301 or send an email to help@bccresearch.com to purchase multi-user licenses.
  Title/Chapter Name Pages Price
Global Markets for Treatments for Syndromes of Dementia and Movement Disorders 228 $6650
Chapter- 1: INTRODUCTION - Complimentary 3 $0
  Show Details
Chapter- 2: EXECUTIVE SUMMARY 2 $250
  Show Details
Chapter- 3: OVERVIEW 10 $438
  Show Details
Chapter- 4: REGULATORY ASPECTS 5 $219
  Show Details
Chapter- 5: NEW DEVELOPMENTS 19 $831
  Show Details
Chapter- 6: GLOBAL MARKETS 13 $569
  Show Details
Chapter- 7: MARKET FOR DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA 32 $1400
  Show Details
Chapter- 8: MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES 24 $1050
  Show Details
Chapter- 9: MARKET FOR MOVEMENT DISORDER SYNDROMES 35 $1531
  Show Details
Chapter- 10: PATENT ANALYSIS 20 $875
  Show Details
Chapter- 11: CURRENT SITUATION 7 $306
  Show Details
Chapter- 12: COMPANY PROFILES 55 $2406
  Show Details
Chapter- 13: APPENDIX I: ABBREVIATIONS 3 $131
  Show Details
 
  List of Tables
  List of Figures
 
  • Purchase Report
  • Download Table of Contents
  • Contact Us